[en] Summary: The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy.
Introduction: To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy.
Methods: A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered soluble ALN compared with generic ALN, denosumab, zoledronic acid and no treatment. Pooled efficacy data derived from the NICE network meta-analysis were
used for bisphosphonate treatments. Two treatment duration scenarios were assessed: 1 year using persistence data derived from an Italian prospective observational study including 144 and 216 postmenopausal osteoporotic women on buffered soluble ALN and oral ALN, respectively, and 3 years. Analyses were conducted for women 60–80 years of age with a bone mineral density Tscore ≤ − 3.0 or with existing vertebral fractures.
Results: In all simulated populations, buffered soluble ALN was dominant (more QALYs, lower costs) compared to denosumab. The cost per QALY gained of buffered soluble ALN compared to generic ALN and no treatment always falls below €20,000 per QALY gained. In the 1-year treatment scenario, zoledronic acid was associated withmore QALY than buffered soluble ALN but
the cost per QALY gained of zoledronic acid compared with buffered soluble ALN was always higher than €70,000, while buffered soluble ALN was dominant in the 3-year treatment scenario.
Conclusion: This study suggests that buffered soluble ALN represents a cost-effective strategy compared with relevant alternative treatments for postmenopausal osteoporosis women in Italy aged 60 years and over.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Hiligsmann, M.
Maggi, S.
Veronese, N.
Sartori, L.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Cost-effectiveness of buffered soluble alendronate 70mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
Borgstrom F, Karlsson L, Ortsater G, Norton N, Halbout P, Cooper C et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15(1):59
Kanis JA, Cooper C, Rizzoli R, Reginster JY Scientific Advisory Board of the European Society for C, Economic Aspects of O, et al (2019) Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res 31(1):15–17
Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705
Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30(11):2155–2165
Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210
Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29(12):2623–2637
McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL et al (2012) Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 23(1):267–276
Hodges LA, Connolly SM, Winter J, Schmidt T, Stevens HN, Hayward M et al (2012) Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm 432(1-2):57–62
Fardellone P, Boëzennec B, Cortet B (2019) Upper gastrointestinal safety with the buffered solution of alendronate 70 mg: 6 years of post-marketing experience. Osteoporos Int 30(2):S253–S773
Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205–224
Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30(1):45–57
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D et al (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 16(2):e1–e5
Hiligsmann M, Reginster JY (2019) Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos Int 30(3):649–658
Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2019) Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49(2):184–196
Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. Semin Arthritis Rheum 50(3):394–400
Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12(5):687–696
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137
Unim B et al (2020) Trends in hip and distal femoral fracture rates in Italy from 2007 to 2017. Bone
Piscitelli P, Chitano G, Johannson H, Brandi ML, Kanis JA, Black DM (2013) Updated fracture incidence rates for the Italian version of FRAX(R). Osteoporos Int 24(3):859–866
Piscitelli P, Tarantino U, Chitano G, Argentiero A, Neglia C, Agnello N, Saturnino L, Feola M, Celi M, Raho C, Distante A, Brandi ML (2011) Updated incidence rates of fragility fractures in Italy: extension study 2002-2008. Clin Cases Miner Bone Metab 8(3):54–61
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382
Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585–590
Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29(10):895–911
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone. 32(5):468–473
Piscitelli P, Neglia C, Feola M, Rizzo E, Argentiero A, Ascolese M, et al (2020) Updated incidence and costs of hip fractures in elderly Italian population. Aging Clin Exp Res 32:2587–2593
Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B (2019) Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporos Int 30(9):1745–1754
Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32(2):198–202
Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML et al (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29:557–566
Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82(4):288–292
NICE 2020. Bisphosphonates for treating osteoporosis. Technology appraisal guidance. Last update 8 July 2019. Access on March 2020 from https://www.nice.org.uk/guidance/ta464/resources/bisphosphonates-for-treating-osteoporosis-pdf-82604905556677
Strom O, Landfeldt E, Garellick G (2015) Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 26(1):315–325
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 105:11–17
Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15(5):604–612
Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2):170–177
Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12(2):159–166
Giusti A, Bianchi G, Barone A, Black DM A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res
Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26(1):361–372
Tremblay E, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11(1):30
Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D et al (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31(11):2093–2102
Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9(4):e027049
Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17(10):1459–1471
Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23(11):2579–2589
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822
Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Torring O et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96(6):1727–1736
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3–44
Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23(1):213–221
